Purpose: To review the current knowledge regarding the pathogenesis of proliferative diabetic vitreoretinopathy (PDVR) and to present recommendations for its clinical staging. Design: Focused literature review and authors’ clinical experience. Results: Although several biochemical mediators may be responsible for the pathogenesis of PDVR, no common biochemical pathway exists. Of those mediators, vascular endothelial growth factor is the one most studied so far. However, since in proliferative diabetic retinopathy (PDR) the thickened posterior vitreous cortex is one of the main factors in the development of proliferations, a consequent shrinkage of the posterior vitreous cortex leads to hemorrhages and tractive retinal detachments. Therefore, PDR should be called PDVR. In consequence, the authors present a new morphological classification of PDVR. Conclusions: There is no consensus about the biochemical pathway responsible for the progression of PDVR. Although several classifications are described in the literature, the classification suggested here is important in the judgment of, the communication about and the therapy of diabetic retinopathy. Furthermore, it is the only reliable classification for predicting the surgical outcome in diabetics.

1.
Adamis AP, Shima DT, Tolentino MJ, Gragoudas ES, Ferrara N, Folkman J, D’Amore PA, Miller JW: Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate. Arch Ophthalmol 1996;114:66–71.
2.
Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, Pasquale LR, Thieme H, Iwamoto MA, Park JE: Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994;331:1480–1487.
3.
Aiello LP, Bursell SE, Clermont A, Duh E, Ishii H, Takagi C, Mori F, Ciulla TA, Ways K, Jirousek M, Smith LE, King GL: Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor. Diabetes 1997;46:1473–1480.
4.
Aiello LP: Perspectives on diabetic retinopathy. Am J Ophthalmol 2003;136:122–135.
5.
Aiello LP: The potential role of PKC beta in diabetic retinopathy and macular edema. Surv Ophthalmol 2002;47:S263–S269.
6.
Akiba J, Ueno N, Chakrabarti B: Molecular mechanisms of posterior vitreous detachment. Graefes Arch Clin Exp Ophthalmol 1993;231:408–412.
7.
Arden GB: The absence of diabetic retinopathy in patients with retinitis pigmentosa: implications for pathophysiology and possible treatment. Br J Ophthalmol 2001;85:366–370.
8.
Armstrong D, Augustin AJ, Spengler R, Al-Jada A, Nickola T, Grus F, Koch F: Detection of vascular endothelial growth factor and tumor necrosis factor alpha in epiretinal membranes of proliferative diabetic retinopathy, proliferative vitreoretinopathy, and macular pucker. Ophthalmologica 1998;212:410–414.
9.
Augustin AJ, Keller A, Koch F, Jurklies B, Dick B: Effect of retinal coagulation status on oxidative metabolite and VEGF in 208 patients with proliferative diabetic retinopathy. Klin Monatsbl Augenheilkd 2001;218:89–94.
10.
Barber AJ, Antonetti DA, Gardner TW: Altered expression of retinal occludin and glial fibrillary acidic protein in experimental diabetes. The Penn State Retina Research Group. Invest Ophthalmol Vis Sci 2000;41:3561–3568.
11.
Barber AJ, Lieth E, Khin SA, Antonetti DA, Buchanan AG, Gardner TW: Neural apoptosis in the retina during experimental and human diabetes: early onset and effect of insulin. J Clin Invest 1998;102:783–791.
12.
Barouch FC, Miyamoto K, Allport JR, Fujita K, Bursell SE, Aiello LP, Luscinskas FW, Adamis AP: Integrin-mediated neutrophil adhesion and retinal leukostasis in diabetes. Invest Ophthalmol Vis Sci 2000;41:1153–1158.
13.
Bodanowitz S, Hesse L, Weinand F, Kroll P: Vitrectomy in diabetic patients with a blind fellow eye. Acta Ophthalmol Scand 1996;74:84–88.
14.
Boeri D, Maiello M, Lorenzi M: Increased prevalence of microthromboses in retinal capillaries of diabetic individuals. Diabetes 2001;50:1432–1439.
15.
Cai J, Boulton M: The pathogenesis of diabetic retinopathy: old concepts and new questions. Eye 2002;16:242–260.
16.
Canton A, Burgos R, Hernandez C, Mateo C, Segura RM, Mesa J, Simo R: Hepatocyte growth factor in vitreous and serum from patients with proliferative diabetic retinopathy. Br J Ophthalmol 2000;84:732–735.
17.
Casaroli Marano RP, Preissner KT, Vilaro S: Fibronectin, laminin, vitronectin and their receptors at newly formed capillaries in proliferative diabetic retinopathy. Exp Eye Res 1995;60:5–17.
18.
Chakrabarti S, Cukiernik M, Hileeto D, Evans T, Chen S: Role of vasoactive factors in the pathogenesis of early changes in diabetic retinopathy. Diabetes Metab Res Rev 2000;16:393–407.
19.
Chantelau E, Kohner EM, Seppel T, Schonau E, Althaus C: Elevation of serum IGF-1 precedes proliferative diabetic retinopathy in Mauriac’s syndrome. Br J Ophthalmol 1997;81:169–170.
20.
Chantelau E: Evidence that upregulation of serum IGF-1 concentration can trigger acceleration of diabetic retinopathy. Br J Ophthalmol 1998;82:725–730.
21.
Chantelau E: Effect of a growth hormone receptor antagonist on proliferative diabetic retinopathy. Ophthalmology 2002;109:2187.
22.
Chaturvedi N, Sjolie AK, Stephenson JM, Abrahamian H, Keipes M, Castellarin A, Rogulja-Pepeonik Z, Fuller JH: Effect of lisinopril on progression of retinopathy in normotensive people with type I diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus. Lancet 1998;351:28–31.
23.
Chiarelli F, Santilli F, Mohn A: Role of growth factors in the development of diabetic complications. Horm Res 2000;53:53–67.
24.
Danis RP, Bingaman DP, Jirousek M, Yang Y: Inhibition of intraocular neovascularization caused by retinal ischemia in pigs by PKC-beta inhibition with LY333531. Invest Ophthalmol Vis Sci 1998;39:171–179.
25.
Davis MD, Norton EWD, Myers FL: The Airlie classification of diabetic retinopathy; in Goldberg MF, Fine SL (eds): Symposium on the Treatment of Diabetic Retinopathy, Washington, US Government Printing Office, 1969, pp. 7–22. USPHS pub No 1890.
26.
Dawson DW, Volpert OV, Gillis P, Crawford SE, Xu H, Benedict W, Bouck NP: Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science 1999;285:245–248.
27.
Dawson VL, Dawson TM: Nitric oxide in neurodegeneration. Prog Brain Res 1998;118:215–229.
28.
Diabetes Control and Complications Trial Study Group: The absence of a glycemic threshold for the development of long-term complications: the perspective of the Diabetes Control and Complications Trial. Diabetes 1996;45:1289–1298.
29.
A modification of the Airlie House classification of diabetic retinopathy. Diabetic Retinopathy Study report No 7. Invest Ophthalmol Vis Sci 1981;21:210–226.
30.
Diabetic Retinopathy Vitrectomy Study Research Group: Early vitrectomy for severe vitreous hemorrhage in diabetic retinopathy: two-year results of a randomized trial. Diabetic Retinopathy Vitrectomy Study report 2. Arch Ophthalmol 1985;103:1644–1652.
31.
Dwyer MS, Melton LJ 3rd, Ballard DJ, Palumbo PJ, Trautmann JC, Chu CP: Incidence of diabetic retinopathy and blindness: a population-based study in Rochester, Minnesota. Diabetes Care 1985;8:316–322.
32.
Early Treatment Diabetic Retinopathy Study Research Group: Grading diabetic retinopathy from stereoscopic color fundus photographs – an extension of the modified Airlie House classification. ETDRS report No 10. Ophthalmology 1991;98:786–806.
33.
Emmerich KH, Kroll P, Berlage F: Fluorescein angiographic long-term controls in patients with proliferative diabetic retinopathy and vitrectomy. Fortschr Ophthalmol 1986;83:474–476.
34.
Faulborn J, Bowald S: Microproliferations in proliferative diabetic retinopathy and their relationship to the vitreous: corresponding light and electron microscopic studies. Graefes Arch Clin Exp Ophthalmol 1985;223:130–138.
35.
Ferrara N: Molecular and biological properties of vascular endothelial growth factor. J Mol Med 1999;77:527–543.
36.
Fong DS: Changing times for the management of diabetic retinopathy. Surv Ophthalmol 2002;47:S238–S245.
37.
Foos RY, Wheeler NC: Vitreoretinal juncture: synchysis senilis and posterior vitreous detachment. Ophthalmology 1982;89:1502–1512.
38.
Foos RY: Vitreoretinal juncture; epiretinal membranes and vitreous. Invest Ophthalmol Vis Sci 1977;16:416–422.
39.
Frank RN: Potential new medical therapies for diabetic retinopathy: protein kinase C inhibitors. Am J Ophthalmol 2002;133:693–698.
40.
Gardner TW, Antonetti DA, Barber AJ, LaNoue KF, Levison SW: Diabetic retinopathy: more than meets the eye. Surv Ophthalmol 2002;47:S253–S262.
41.
Goldfarb S, Ziyadeh FN, Kern EF, Simmons DA: Effects of polyol-pathway inhibition and dietary myo-inositol on glomerular hemodynamic function in experimental diabetes mellitus in rats. Diabetes 1991;40:465–471.
42.
Growth Hormone Antagonist for Proliferative Diabetic Retinopathy Study Group: The effect of a growth hormone receptor antagonist drug on proliferative diabetic retinopathy. Ophthalmology 2001;108:2266–2272.
43.
Hammes HP, Alt A, Niwa T, Clausen JT, Bretzel RG, Brownlee M, Schleicher ED: Differential accumulation of advanced glycation end products in the course of diabetic retinopathy. Diabetologia 1999;42:728–736.
44.
Hammes HP, Lin J, Bretzel RG, Brownlee M, Breier G: Upregulation of the vascular endothelial growth factor/vascular endothelial growth factor receptor system in experimental background diabetic retinopathy of the rat. Diabetes 1998;47:401–406.
45.
Hammes HP, Lin J, Renner O, Shani M, Lundqvist A, Betsholtz C, Brownlee M, Deutsch U: Pericytes and the pathogenesis of diabetic retinopathy. Diabetes 2002;51:3107–3112.
46.
Hammes HP, Wellensiek B, Kloting I, Sickel E, Bretzel RG, Brownlee M: The relationship of glycemic level to advanced glycation end-product (AGE) accumulation and retinal pathology in the spontaneous diabetic hamster. Diabetologia 1998;41:165–170.
47.
Hata Y, Clermont A, Yamauchi T, Pierce EA, Suzuma I, Kagokawa H, Yoshikawa H, Robinson GS, Ishibashi T, Hashimoto T, Umeda F, Bursell SE, Aiello LP: Retinal expression, regulation, and functional bioactivity of prostacyclin-stimulating factor. J Clin Invest 2000;106:541–550.
48.
Hendrikse F, Yeo KT: Role of the vitreous body in diabetic retinopathy. Klin Monatsbl Augenheilkd 1993;203:319–323.
49.
Hernandez C, Lecube A, Segura RM, Sararols L, Simo R: Nitric oxide and vascular endothelial growth factor concentrations are increased but not related in vitreous fluid of patients with proliferative diabetic retinopathy. Diabet Med 2002;19:655–660.
50.
Hesse L, Bodanowitz S, Hühnermann M, Kroll P: Prediction of visual acuity after early vitrectomy in diabetics. Ger J Ophthalmol 1996;5:257–261.
51.
Hesse L, Heller G, Kraushaar N, Wesp A, Schroeder B, Kroll P: The predictive value of a classification for proliferative diabetic vitreoretinopathy. Klin Monatsbl Augenheilkd 2002;219:46–49.
52.
Hesse L, Kroll P: Enzymatically induced posterior vitreous detachment in proliferative diabetic vitreoretinopathy. Klin Monatsbl Augenheilkd 1999;214:84–89.
53.
Hesse L, Kroll P: TPA-assisted vitrectomy for proliferative diabetic retinopathy. Retina 2000;20:317–318.
54.
Hesse L, Kroll P: What is the ophthalmologic recommendation for managing diabetes with reference to diabetic retinopathy. Internist (Berl) 1993;34:477.
55.
Hoerle S, Gruner F, Kroll P: Epidemiology of diabetes-induced blindness – a review. Klin Monatsbl Augenheilkd 2002;219:777–784.
56.
Hoerle S, Poestgens H, Schmidt J, Kroll P: Effect of pars plana vitrectomy for proliferative diabetic vitreoretinopathy on preexisting diabetic maculopathy. Graefes Arch Clin Exp Ophthalmol 2002;240:197–201.
57.
Hovener G: The influence of refraction on diabetic retinopathy. Klin Monatsbl Augenheilkd 1975;167:733–736.
58.
Ishida S, Shinoda K, Kawashima S, Oguchi Y, Okada Y, Ikeda E: Coexpression of VEGF receptors VEGF-R2 and neuropilin-1 in proliferative diabetic retinopathy. Invest Ophthalmol Vis Sci 2000;41:1649–1656.
59.
Ishii H, Jirousek MR, Koya D, Takagi C, Xia P, Clermont A, Bursell SE, Kern TS, Ballas LM, Heath WF, Stramm LE, Feener EP, King GL: Amelioration of vascular disfunctions in diabetic rats by an oral PKC beta inhibitor. Science 1996;272:728–731.
60.
Joussen AM, Fauser S, Krohne TU, Lemmen KD, Lang GE, Kirchhof B: Diabetic retinopathy: pathophysiology and therapy of hypoxia-induced inflammation. Ophthalmologe 2003;100:363–370.
61.
Joussen AM, Kirchhof B, Gottstein C: Molecular mechanisms of vasculogenesis and angiogenesis: what regulates vascular growth? Ophthalmologe 2003;100:284–291.
62.
Joussen AM: Angiogenesis in ophthalmology. 2. Current considerations on the pathogenesis of diabetic and hypoxia-induced retinopathy. Ophthalmologe 2003;100:361–362.
63.
Kador PF, Takahashi Y, Wyman M, Ferris F 3rd: Diabetes-like proliferative retinal changes in galactose-fed dogs. Arch Ophthalmol 1995;113:352–354.
64.
Kagami S, Border WA, Miller DE, Noble NA: Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells. J Clin Invest 1994;93:2431–2437.
65.
Kerty E, Russell D, Bakke SJ, Nyberg-Hansen R, Rootwell K: Regional cerebral blood flow (rCBF) and cerebral vasoreactivity in patients with retinal ischaemic symptoms. J Neurol Neurosurg Psychiatry 1989;52:1345–1350.
66.
Klein R, Klein BE, Moss SE, Cruickshanks KJ: The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XVII. The 14-year incidence and progression of diabetic retinopathy and associated risk factors in type I diabetes. Ophthalmology 1998;105:1801–1815.
67.
Klein R, Klein BE, Moss SE: Epidemiology of proliferative diabetic retinopathy. Diabetes Care 1992;15:1875–1891.
68.
Klein R: Has the frequency of proliferative diabetic retinopathy declined in the US. Diabetes Care 2003;26:2691–2692.
69.
Klein R: Prevention of visual loss from diabetic retinopathy. Surv Ophthalmol 2002;47:S246–S252.
70.
Kohno T, Sorgente N, Goodnight R, Ryan SJ: Alterations in the distribution of fibronectin and laminin in the diabetic human eye. Invest Ophthalmol Vis Sci 1987;28:515–521.
71.
Kohno T, Sorgente N, Ishibashi T, Goodnight R, Ryan SJ: Immunofluorescent studies of fibronectin and laminin in the human eye. Invest Ophthalmol Vis Sci 1987;28:506–514.
72.
Kroll P, Meyer-Rusenberg HW, Berg P: Does vitrectomy in case of proliferative diabetic retinopathy lead to a better intraocular metabolism? Fortschr Ophthalmol 1986;83:471–473.
73.
Kroll P, Meyer-Rusenberg HW, Busse H: Recommendation for staging of proliferative diabetic retinopathy. Fortschr Ophthalmol 1987;84:360–363.
74.
Kroll P, Wiegand W, Schmidt J: Vitreopapillary traction in proliferative diabetic vitreoretinopathy. Br J Ophthalmol 1999;83:261–264.
75.
Krumpaszky HG, Klauss V: Epidemiology of blindness and eye disease. Ophthalmologica 1996;210:1–86.
76.
Lakshminarayanan S, Antonetti DA, Gardner TW, Tarbell JM: Effect of VEGF on retinal microvascular endothelial hydraulic conductivity: the role of NO. Invest Ophthalmol Vis Sci 2000;41:4256–4261.
77.
Limb GA, Hickman-Casey J, Hollifield RD, Chignell AH: Vascular adhesion molecules in vitreous from eyes with proliferative diabetic retinopathy. Invest Ophthalmol Vis Sci 1999;40:2453–2457.
78.
Lonneville YH, Ozdek SC, Onol M, Yetkin I, Gurelik G, Hasanreisoglu B: The effect of blood glucose regulation on retinal nerve fiber layer thickness in diabetic patients. Ophthalmologica 2003;217:347–350.
79.
Malecaze F, Clamens S, Simorre-Pinatel V, Mathis A, Chollet P, Favard C, Bayard F, Plouet J: Detection of vascular endothelial growth factor messenger RNA and vascular endothelial growth factor-like activity in proliferative diabetic retinopathy. Arch Ophthalmol 1994;112:1476–1482.
80.
Matsugi T, Chen Q, Anderson DR: Contractile responses of cultured bovine retinal pericytes to angiotensin II. Arch Ophthalmol 1997;115:1281–1285.
81.
Merimee TJ: Diabetic retinopathy: a synthesis of perspectives. N Engl J Med 1990;322:978–983.
82.
Mitamura Y, Takeuchi S, Ohtsuka K, Matsuda A, Yamamoto T, Yamamoto S, Hiraiwa N, Kusakabe M: Tenascin-C levels in the vitreous of patients with proliferative vitreoretinopathy. Ophthalmologica 2003;217:422–425.
83.
Murata T, Nagai R, Ishibashi T, Inomuta H, Ikeda K, Horiuchi S: The relationship between accumulation of advanced glycation end products and expression of vascular endothelial growth factor in human diabetic retinas. Diabetologia 1997;40:764–769.
84.
Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, Kojima Y, Furuyoshi N, Shichiri M: Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995;28:103–117.
85.
Okamoto N, Tobe T, Hackett SF, Ozaki H, Vinores MA, LaRochelle W, Zack DJ, Campochiaro PA: Transgenic mice with increased expression of vascular endothelial growth factor in the retina: a new model of intraretinal and subretinal neovascularization. Am J Pathol 1997;151:281–291.
86.
Oku H, Kida T, Sugiyama T, Hamada J, Sato B, Ikeda T: Possible involvement of endothelin-1 and nitric oxide in the pathogenesis of proliferative diabetic retinopathy. Retina 2001;21:647–651.
87.
Papapetropoulos A, Garcia-Cardena G, Madri JA, Sessa WC: Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells. J Clin Invest 1997;100:3131–3139.
88.
Porta M, Bandello F: Diabetic retinopathy: a clinical update. Diabetologia 2002;45:1617–1634.
89.
Porta M, Sjoelie AK, Chaturvedi N, Stevens L, Rottiers R, Veglio M, Fuller JH; EURODIAB Prospective Complications Study Group: Risk factors for progression to proliferative diabetic retinopathy in the EURODIAB Prospective Complications Study. Diabetologia 2001;44:2203–2209.
90.
Poulsen JE: The Houssay phenomenon in man: recovery from retinopathy in a case of diabetes with Simmond’s disease. Diabetes 1953;2:7–12.
91.
Rungger-Brandle E, Dosso AA, Leuenberger PM: Glial reactivity, an early feature of diabetic retinopathy. Invest Ophthalmol Vis Sci 2000;41:1971–1980.
92.
Rymaszewski Z, Cohen RM, Chomczynski P: Human growth hormone stimulates proliferation of human retinal microvascular endothelial cells in vitro. Proc Natl Acad Sci USA: 1991;88:617–621.
93.
Sato Y, Lee Z: The subclassification and long-term prognosis of preproliferative diabetic retinopathy. Jpn J Ophthalmol 2002;46:323–329.
94.
Schalekamp MADH: Renin-angiotensin system components and endothelial proteins as markers of diabetic microvascular disease. Clin Invest 1993;71:S3–S6.
95.
Schulze S, Schulze S, Schmidt J, Kroll P: Air endotamponade in 52 vitrectomies due to proliferative diabetic retinopathy – retrospective comparison with 40 vitrectomies without endotamponade. Klin Monatsbl Augenheilkd 2000;217:329–333.
96.
Sebag J, Buckingham B, Charles MA, Reiser K: Biochemical abnormalities in vitreous of humans with proliferative diabetic retinopathy. Arch Ophthalmol 1992;110:1472–1476.
97.
Sebag J, Buzney SM, Belyea DA, Kado M, McMeel JW, Trempe CL: Posterior vitreous detachment following panretinal laser photocoagulation. Graefes Arch Clin Exp Ophthalmol 1990;228:5–8.
98.
Sebag J, Hageman GS: Interfaces. Rome, Fondazione GB Bietti, 2000, chap IV, pp 62–65.
99.
Sebag J: The Vitreous – Structure, Function and Pathobiology. New York, Springer, 1989, pp 106–107.
100.
Sebag J: Diabetic vitreopathy. Ophthalmology 1996;103:205–206.
101.
Shea M: Early vitrectomy in proliferative diabetic retinopathy. Arch Ophthalmol 1983;101:1204–1205.
102.
Simo R, Lecube A, Segura RM, Garcia Arumi J, Hernandez C: Free insulin-like growth factor-I and vascular endothelial growth factor in the vitreous fluid of patients with proliferative diabetic retinopathy. Am J Ophthalmol 2002;134:376–382.
103.
Sjolie AK, Stephenson J, Aldington S, Kohner E, Janka H, Stevens L, Fuller J: Retinopathy and vision loss in insulin-dependent diabetes in Europe. Ophthalmology 1997;104:252–260.
104.
Smith JA, Davis CL, Burgess GM: Prostaglandin E2-induced sensitization of bradykinin-evoked responses in rat dorsal root ganglion neurons is mediated by cAMP-dependent protein kinase A. Eur J Neurosci 2000;12:3250–3258.
105.
Smith LE, Shen W, Perruzzi C, Soker S, Kinose F, Xu X, Robinson G, Driver S, Bischoff J, Zhang B, Schaeffer JM, Senger DR: Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor. Nat Med 1999;5:1390–1395.
106.
Sozmen EY, Sozmen B, Delen Y, Onat T: Catalase/superoxide dismutase (SOD) and catalase/paraoxonase (PON) ratios may implicate poor glycemic control. Arch Med Res 2001;32:283–287.
107.
Spranger J, Hammes HP, Preissner KT, Schatz H, Pfeiffer AF: Release of the angiogenesis inhibitor angiostatin in patients with proliferative diabetic retinopathy: association with retinal photocoagulation. Diabetologia 2000;43:1404–1407.
108.
Stavri GT, Zachary IC, Baskerville PA, Martin JF, Erusalimsky JD: Basic fibroblast growth factor upregulates the expression of vascular endothelial growth factor in vascular smooth muscle cells: synergistic interaction with hypoxia. Circulation 1995;92:11–14.
109.
Stevens MJ, Dananberg J, Feldman EL, Lattimer SA, Kamijo M, Thomas TP, Shindo H, Sima AA, Greene DA: The linked roles of nitric oxide, aldose reductase and Na+, K+-ATPase in the slowing of nerve conduction in the streptozotocin diabetic rat. J Clin Invest 1994;94:853–859.
110.
Stitt AW, Gardiner TA, Archer DB: Histological and ultrastructural investigation of retinal microaneurysm development in diabetic patients. Br J Ophthalmol 1995;79:362–367.
111.
Stitt AW: Advanced glycation: an important pathological event in diabetic and age related ocular disease. Br J Ophthalmol 2001;85:746–753.
112.
Stitt AW: The role of advanced glycation in the pathogenesis of diabetic retinopathy. Exp Mol Pathol 2003;75:95–108.
113.
Takahashi T, Hato F, Yamane T, Fukumasu H, Suzuki K, Ogita S, Nishizawa Y, Kitagawa S: Activation of human neutrophil by cytokine-activated endothelial cells. Circ Res 2001;88:422–429.
114.
The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977–986.
115.
Tsai DC, Chiou SH, Lee FL, Chou CK, Chen SJ, Peng CH, Kuo YH, Chen CF, Ho LL, Hsu WM: Possible involvement of nitric oxide in the progression of diabetic retinopathy. Ophthalmologica 2003;217:342–346.
116.
UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837–853.
117.
UK Prospective Diabetes Study Group:Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317:703–713.
118.
Vlodavsky I, Bar-Shavit R, Ishai-Michaeli R, Bashkin P, Fuks Z: Extracellular sequestration and release of fibroblast growth factor: a regulatory mechanism? Trends Biochem Sci 1991;16:268–271.
119.
Wilkinson CP, Ferris FL 3rd, Klein RE, Lee PP, Agardh CD, Davis M, Dills D, Kampik A, Pararajasegaram R, Verdaguer JT; Global Diabetic Retinopathy Project Group: Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology 2003;110:1677–1682.
120.
Wilkinson-Berka JL, Kelly DJ, Gilbert RE: The interaction between the renin-angiotensin system and vascular endothelial growth factor in the pathogenesis of retinal neovascularization in diabetes. J Vasc Res 2001;38:527–535.
121.
Williams B, Gallacher B, Patel H, Orme C: Glucose-induced protein kinase C activation regulates vascular permeability factor mRNA expression and peptide production by human vascular smooth muscle cells in vitro. Diabetes 1997;46:1497–1503.
122.
Yu DY, Cringle SJ, Alder VA: The response of rat vitreal oxygen tension to stepwise increases in inspired percentage oxygen. Invest Ophthalmol Vis Sci 1990;31:2493–2499.
123.
Ziche M, Morbidelli L, Choudhuri R, Zhang HT, Donnini S, Granger HJ, Bicknell R: Nitric oxide synthase lies downstream from vascular endothelial growth factor-induced but not basic fibroblast growth factor-induced angiogenesis. J Clin Invest 1997;99:2625–2634.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.